Skip to main content
Theranexus logo

Theranexus — Investor Relations & Filings

Ticker · ALTHX ISIN · FR0013286259 LEI · 969500BFCV6IC7MFQP20 PA Manufacturing
Open in API
Filings indexed 286 across all filing types
Latest filing 2019-09-26 Earnings Release
Country FR France
Listing PA ALTHX

About Theranexus

https://www.theranexus.com/en/

THX Pharma (formerly Theranexus) is an innovative, clinical-stage biopharmaceutical company that emerged from the French Alternative Energies and Atomic Energy Commission (CEA). The company specializes in developing treatments for rare neurological disorders. It leverages a unique platform for the identification and characterization of advanced therapy drug candidates. Its lead program is a drug candidate in clinical development for Batten disease, a rare neurodegenerative disorder.

Recent filings

Filing Released Lang Actions
THERANEXUS ANNOUNCES ITS FIRST HALF 2019 RESULTS
Earnings Release Classification · 99% confidence The document is titled "THERANEXUS ANNOUNCES ITS FIRST HALF 2019 RESULTS" and contains detailed financial tables (H1-2019 vs H1-2018) and management commentary on operating income, net income, and cash position for the first half of the year. It also discusses clinical trial progress (Phase I, Phase II) and partnerships. This content strongly indicates a comprehensive report covering a period shorter than a full year, which aligns with the definition of an Interim / Quarterly Report (IR). Although it mentions the full half-year report will be available later, the document itself contains the actual results and analysis, making it the report, not just an announcement of the report (RPA). H2 2019
2019-09-26 English
THERANEXUS ANNONCE SES RÉSULTATS DU PREMIER SEMESTRE 2019
Earnings Release Classification · 99% confidence The document is titled "THERANEXUS ANNONCE SES RÉSULTATS DU PREMIER SEMESTRE 2019" (Theranexus announces its results for the first half of 2019). It contains a detailed table of financial results for the first semester (S1-2019 vs S1-2018), discusses operational expenses, net result, and cash position as of June 30, 2019. It also provides updates on clinical programs (THN102, THN201, THN101). This content structure—financial highlights for a specific interim period (first semester) combined with operational updates—is characteristic of an Interim/Quarterly Report. The text explicitly mentions: "Résultats financiers du premier semestre 2019" and "Le Rapport Semestriel de la société pour le premier Semestre 2019 sera disponible...". This strongly aligns with the definition of an Interim / Quarterly Report (Code: IR). It is not a brief announcement (RPA) as it contains substantial financial detail and operational narrative, nor is it the full Annual Report (10-K). H1 2019
2019-09-26 French
A NEW MILESTONE REACHED FOR THERANEXUS: INCLUSION OF LAST PATIENT IN PHASE II TRIAL FOR THN102 IN PARKINSON'S PATIENTS
Regulatory Filings Classification · 95% confidence The document is a press release dated September 24, 2019, announcing a clinical trial milestone: the inclusion of the last patient in a Phase II trial for the drug candidate THN102 in Parkinson's patients. It details the trial's purpose, design, quotes management and a key investigator, and provides company background. This type of announcement, focusing on operational progress, clinical trial updates, and future results expectations, is characteristic of an Investor Presentation (IP) or a general press release related to R&D progress. Since it is a detailed update on clinical progress and strategy aimed at investors, Investor Presentation (IP) is the most fitting category, as it often includes such detailed operational updates, even if presented as a press release rather than a formal slide deck. It is not a formal regulatory filing like 10-K or IR, nor is it a simple Earnings Release (ER) or a Report Publication Announcement (RPA).
2019-09-24 English
NOUVELLE ETAPE FRANCHIE POUR THERANEXUS : INCLUSION DU DERNIER PATIENT DANS L'ETUDE DE PHASE 2 POUR THN102 DANS LA MALADIE DE PARKINSON
Regulatory Filings Classification · 87% confidence The document is a press release dated September 24, 2019, announcing that Theranexus has enrolled its last patient in a Phase 2 clinical study for THN102 in Parkinson's disease. It details the study's objectives (tolerance and efficacy on non-motor symptoms), the treatment protocol (cross-over design with THN102, modafinil/flecainide combination, and placebo), and provides quotes from management and a key opinion leader. It also mentions the expected results date (Q1 2020) and includes boilerplate 'About' sections. This content structure—a news announcement about a clinical trial milestone (patient enrollment completion) and expected results—is characteristic of an Earnings Release (ER) or a general press release announcing operational progress, which often overlaps with the content of an Investor Presentation (IP) or a general update. However, since it is a formal announcement of operational progress and future results, and not a transcript (CT), a formal financial report (10-K, IR), or a specific regulatory filing like DIRS or DIV, the most fitting category for a significant operational update that precedes formal financial reporting is the Earnings Release (ER), as these press releases often accompany or precede quarterly financial summaries, or the Investor Presentation (IP) if it were structured as a slide deck. Given the format is a press release announcing a major operational milestone and setting expectations for results, it functions as a key piece of investor communication. Since it is not a formal financial report, but a news update, and it is not explicitly a presentation (IP), the closest fit among the provided options for a significant, time-sensitive operational update is often the Earnings Release (ER), although it is not strictly an earnings report. Alternatively, it could be classified as Regulatory Filing (RNS) if it were a mandatory filing, but the content strongly suggests a proactive investor communication. Given the focus on clinical trial progress and future results, it aligns best with the type of material disseminated around earnings periods or as a standalone update. I will classify it as an Earnings Release (ER) as it communicates key operational performance indicators (trial progress) and sets expectations for future results, which is a common function of ERs, even if it lacks specific financial figures in this excerpt. If 'RNS' were chosen, it would be a fallback, but ER captures the intent better.
2019-09-24 French
THERANEXUS ANNONCE L'INCLUSION DU DERNIER SUJET DANS SON ÉTUDE DE PHASE 1B POUR THN201
Regulatory Filings Classification · 95% confidence The document is a press release dated September 17, 2019, announcing that Theranexus has completed the enrollment of the last subject in its Phase 1b study for THN201, comparing it against the standard of care for neurocognitive disorders in Alzheimer's disease. It details the study design (152 healthy subjects, double-blind, randomized) and mentions that results are expected in Q4 2019. This content—an announcement about clinical trial progress and key operational milestones—does not fit the definitions for a formal financial report (10-K, IR, ER, MRQ) or a specific regulatory filing. It is a general corporate update regarding R&D progress. Since it is not a formal financial report, an earnings release, or a specific regulatory filing like DIRS or DIV, the most appropriate general category for a significant corporate announcement that doesn't fit elsewhere is 'Regulatory Filings' (RNS), as it serves as a general regulatory/corporate disclosure, although 'Investor Presentation' (IP) or 'Management Reports' (MDA) might seem close, this is a press release format announcing trial progress, which often falls under general disclosure/RNS if no other specific category applies. Given the options, RNS is the best fit for a general corporate news announcement not covered by the more specific financial or meeting codes.
2019-09-17 French
THERANEXUS ANNOUNCES INCLUSION OF LAST SUBJECT IN ITS PHASE IB TRIAL OF THN201
Regulatory Filings Classification · 99% confidence The document is a press release announcing a clinical trial milestone: the inclusion of the last subject in a Phase Ib trial for the drug candidate THN201 for Alzheimer's disease-related neurocognitive disorders. It details the study design, context, and expected results timeline. This type of announcement, focusing on operational progress in drug development rather than comprehensive financial results (10-K, IR) or management changes (MANG), is typically classified as a general regulatory or corporate update. Since it is not a formal financial report, an earnings release, or a specific legal/governance filing, it fits best under the general 'Regulatory Filings' (RNS) category, which serves as a broad category for corporate news releases that don't fit elsewhere, especially those related to clinical progress.
2019-09-17 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.